Cancer cells have been found to express immunoglobulin G (IgG), but the exact functions and underlying mechanisms of cancerderived IgG remain elusive. In this study, we first confirmed that downregulation of IgG restrained the growth and proliferation of cancer cells in vitro and in vivo. To elucidate its mechanism, we carried out a co-immunoprecipitation assay in HeLa cells and identified 27 potential IgG-interacting proteins. Among them, receptor of activated protein kinase C 1 (RACK1), ras-related nuclear protein (RAN) and peroxiredoxin 1 (PRDX1) are closely related to cell growth and oxidative stress, which prompted us to investigate the mechanism of action of IgG in the above phenomena. Upon confirmation of the interactions between IgG and the three proteins, further experiments revealed that downregulation of cancer-derived IgG lowered levels of intracellular reactive oxygen species (ROS) by enhancing cellular total antioxidant capacity. In addition, a few ROS scavengers, including catalase (CAT), dimethylsulfoxide (DMSO), n-acetylcysteine (NAC) and superoxide dismutase (SOD), further inhibited the growth of IgG-deficient cancer cells through suppressing mitogen-activated protein kinase/extracellular-regulated kinase (MAPK/ERK) signaling pathway induced by a low level of intracellular ROS, whereas exogenous hydrogen peroxide (H 2 O 2 ) at low concentration promoted their survival via increasing intracellular ROS levels. Similar results were obtained in an animal model and human tissues. Taken together, our results demonstrate that cancer-derived IgG can enhance the growth and proliferation of cancer cells via inducing the production of ROS at low level. These findings provide new clues for understanding tumor proliferation and designing cancer therapy.
Cancer cells have been found to express immunoglobulin G (IgG), but the exact functions and underlying mechanisms of cancerderived IgG remain elusive. In this study, we first confirmed that downregulation of IgG restrained the growth and proliferation of cancer cells in vitro and in vivo. To elucidate its mechanism, we carried out a co-immunoprecipitation assay in HeLa cells and identified 27 potential IgG-interacting proteins. Among them, receptor of activated protein kinase C 1 (RACK1), ras-related nuclear protein (RAN) and peroxiredoxin 1 (PRDX1) are closely related to cell growth and oxidative stress, which prompted us to investigate the mechanism of action of IgG in the above phenomena. Upon confirmation of the interactions between IgG and the three proteins, further experiments revealed that downregulation of cancer-derived IgG lowered levels of intracellular reactive oxygen species (ROS) by enhancing cellular total antioxidant capacity. In addition, a few ROS scavengers, including catalase (CAT), dimethylsulfoxide (DMSO), n-acetylcysteine (NAC) and superoxide dismutase (SOD), further inhibited the growth of IgG-deficient cancer cells through suppressing mitogen-activated protein kinase/extracellular-regulated kinase (MAPK/ERK) signaling pathway induced by a low level of intracellular ROS, whereas exogenous hydrogen peroxide (H 2 O 2 ) at low concentration promoted their survival via increasing intracellular ROS levels. Similar results were obtained in an animal model and human tissues. Taken together, our results demonstrate that cancer-derived IgG can enhance the growth and proliferation of cancer cells via inducing the production of ROS at low level. These findings provide new clues for understanding tumor proliferation and designing cancer therapy. The classic concept that immunoglobulins were produced only by B lymphocytes and plasma cells was challenged when many non-lymphoid lineage cells were found to have the ability to produce IgG. These include cancer cells such as breast cancer cells, [1] [2] [3] colorectal cancer cells, 4, 5 prostate cancers cells, 6 papillary thyroid cancer cells 7 and soft tissue tumors, 8 human umbilical endothelial cells, 9 testicular spermatogenic cells, 10 epididymal epithelial cells, 10 human and mouse neurons 11, 12 and eyes. 13 It was reported that IgG secreted by human cancers promoted growth and survival of tumor cells. 1 IgG detected in a wide variety of neoplasms was found to correlate with proliferation markers and tumor grades. 1, 3, 5 Furthermore, knockdown of the expression of heavy-chain genes of immunoglobulin isotypes through siRNA suppressed cancer cell growth in vitro and in vivo. 14 However, the regulatory mechanism of the above biological effects remains uncertain.
In this study, we designed and performed a series of experiments to investigate the cellular mechanism of cancerderived IgG. We found that downregulation of IgG with siRNA silencing inhibited the growth and proliferation of a variety of cancer cell types in vitro and in vivo. Subsequently, we performed a co-immunoprecipitation coupled liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis to identify potential IgG-interacting proteins. Among the 27 candidate IgG-binding proteins obtained, guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 (GNB2L1; RACK1) and RAN were involved in cellular growth, and PRDX1, an antioxidase, participated in cellular antioxidate and proliferation. The above three proteins are more closely connected with cell growth and proliferation, compared with other candidate proteins. After confirmation of the interactions between cancer-derived IgG and the above three proteins, we explored the biological activity of cancer-derived IgG in cellular oxidative stress and proliferation.
Results
Reduction of cancer-derived IgG inhibits cell growth in vitro and in vivo. First, we established IgG expression in a number of cancer cell lines including HeLa, HEp-2 and PC3 and cervical carcinoma tissues (Supplementary Figure S1) . In order to verify the identities of the above cell lines, short tandem repeat identifications of HeLa, HEp-2 and PC3 cell lines were performed and the profiles showed 100% confirmation with those provided by the American Type Culture Collection (ATCC) (Supplementary Figures S2a-c) . Then, HeLa cells were transfected with IGHG1 siRNA or scrambled siRNA. Immunoblotting and real-time quantitative reverse transcription PCR (RT-qPCR) were performed to detect the expression of IgGg. The results showed that downregulation of cancer-derived IgG markedly reduced the expression of IgGg at both the protein and mRNA HeLa cells treated with IGHG1 siRNA or scrambled siRNA were analyzed marphotogically 3 days before and 3 days after the treatment. It was found that the number of deficient cells was significantly less than that of cells treated with scrambled siRNA 3 days after the treatment (Figure 1d, right panel) . Flow cytometry assay revealed a significant reduction of cell population in the S phase after IgG knockdown in HeLa cells with siRNA ( Figure 1i) . Similar results were obtained in HeLa cell lines stably expressing IGHG1 shRNA or control shRNA (Supplementary Figures S3b-f) . We tested whether IGHG1 reduction from HeLa cells inhibits tumor growth. We injected subcutaneously control shRNA and IGHG1 shRNA1 cells into BALB/c nude mice. In contrast to control shRNA cells, which formed large tumors within 43 days (6 out of 6 mice), all six mice injected with IGHG1 shRNA cells led to greatly reduced tumor growth (Figure 1g ).
Identification and functional classification of cancerderived IgG-interacting proteins. We then screened potential cancer-derived IgG-interacting proteins with co-immunoprecipitation combined with LC-MS/MS. HeLa cell lysate was immunoprecipitated with mouse antihuman IgG g antibody and normal mouse IgG. The immunocomplex was run in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and detected with silver staining.
Three prominently enhanced bands were subjected to protein identification with LC-MS/MS (Figure 2b marked a-c). The MS data were analyzed with the National Center for Biotechnology Information database. The strategy used to screen cancer-derived IgG-associated proteins is illustrated in Figure 2a . After analyzing the data, we eventually identified 27 putative cancer-derived IgG-associated proteins (Supplementary Table S1 ).
To understand the functions of these potential IgG binding proteins, we carried out functional annotations with the Database for Annotation, Visualization and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov/). The annotation revealed that the proteins were localized in the cytoplasm, the nucleus and the mitochondria and were involved in various biological processes such as cell growth and proliferation, protein synthesis, antioxidants and so on (Supplementary Table S2 ). Among proteins with the annotated functions, RACK1, RAN and PRDX1 were classified as being involved in cell growth and proliferation. PRDX1 is an antioxidant, participating in cellular oxidative stress. Based on the evidence of IgG involvement in cancer cell growth and oxidative stress, we selected RACK1, RAN and PRDX1 for further investigation.
Cancer-derived IgG interacts with RACK1, RAN and PRDX1 in cell cytoplasm and forms a macro-protein complex. To further verify the interactions between cancerderived IgG and RACK1, RAN and PRDX1, we performed independent precipitations with a mouse anti-human IgGg antibody or normal mouse IgG. The results confirmed that the three proteins could bind to endogenous IgG independently (Figure 3a) .
In a similar manner, It was found that RAN or PRDX1 could bind to RACK1, and RAN could bind to PRDX1 (Figures 3b  and c) . Confocal immunofluorescence microscopy revealed that IgG colocalized with RACK1, RAN, and PRDX1 well in the cytoplasm of HeLa cells (Figure 3d ), RACK1 colocalized with RAN or PRDX1 well in the cytoplasm, and PRDX1 and RAN were also colocalized well in the cytoplasm (Figure 3e ). To test the crossreactivity between anti-human IgGg and RACK1, RAN, PRDX1 or anti-human RACK1 and RAN, PRDX1 or anti-human RAN and PRDX1, we synthetized RACK1, RAN and PRDX1 peptides with 20 amino acids (Supplementary Figure S4a) as antigens and completed dot-blot immunoassay. The results showed that the above four antibodies didn't identify other three peptides except for its own antigen ( Supplementary Figures S4b-e) .
Reduction of cancer-derived IgG enhances cellular total antioxidant capacity. To explore the mechanism of cancerderived IgG involving in cellular oxidative stress response, we performed a series of experiments to investigate the possible effect of IgG on cell total antioxidant capacity including antioxidant enzymes and small molecular antioxidants. It was found that knockdown of IgG markedly enhanced cellular total antioxidant capacity (T-AOC) (Figure 4a ) including the expression levels or activities of various antioxidant enzymes and contents of small molecule antioxidants. Immunoblotting and RT-qPCR were performed in HeLa cells to detect the expression of PRDX1 Table S1) after knockdown of IgG. Results showed that downregulation of IgG dramatically elevated the expression of PRDX1 at both protein and mRNA levels (Figures 4c and d) . Then, the activities of a few key antioxidant enzymes including total SOD, Mn-SOD, CuZn-SOD, CAT, glutathione reductase (GR) and glutathione peroxidase (GPx) were measured. Results showed that the activities of the above antioxidant enzymes in IgG-deficient cells were significantly higher than those of the control cells ( Reduction of cancer-derived IgG lowers levels of intracellular ROS. It is well known that nonenzymatic and enzymatic antioxidants in vivo, including ascorbic acid, vitamin E, GSH, SOD, CAT, GR and GPx, can effectively eliminate ROS such as superoxide anion (O 2 À ), H 2 O 2 and hydroxyl free radical (OH Á ). [15] [16] [17] [18] [19] Our results indicated that knockdown of cancer-derived IgG significantly raised the activities of the above antioxidant enzymes. Therefore, we examined the effect of IgG on levels of intracellular O 2 À with a dihydroethidium (DHE) assay and H 2 O 2 with a dichlorofluorescein diacetate (DCFH-DA) assay. Flowcytometry and confocal microscopy analysis showed that downregulation of IgG significantly reduced DHE or DCF fluorescence intensity (Figures 5a and c) . DHE and DCFH-DA assay were also performed in HEp-2 and PC3 cells under the same conditions and similar results were obtained (Figures 5b and  d) . We also investigated the effect of IgG on endogenous H 2 O 2 in cytoplasm and cell culture medium directly. Results revealed that H 2 O 2 level was significantly decreased in both cytoplasm and culture medium of IgG-deficient cells (Figures 5e and f, left panel) . This was in good agreement IgG enhances tumor growth by inducing the production of ROS in vivo. We next tested the in vivo effects of ROS on IgG promoting tumor growth. Six BALB/c nude mice were injected with control shRNA cells (group 1) or IGHG1 shRNA cells (group 2) into the bilateral groin. In addition, another set of IGHG1 shRNA cells was also injected into the bilateral groin of six BALB/c nude mice. When the diameters of the tumors were 40.3 cm after injection, H 2 O 2 (2 mM) was directly injected into the tumor body (group 3). Tumor growth was monitored externally using vernier calipers for 8 weeks. In contrast to group 1 mice, which formed large tumors within 49 days (six out of six mice), group 2 mice formed very small tumors, while group 3 mice reversed the above phenomenon and their tumors obviously restored growth (Figures 7a and  b) . Moreover, results showed that DHE or DCF mean density of tumors tissues from group 2 mice was lower than that of group 1 mice, but that of group 3 mice was higher than that of group 2 mice. The results of MDA content, the expression of proliferating cell nuclear antigen (PCNA) and Ki67 and ERK phosphorylation were similar to those mentioned above (Figures 7d, e and Supplementary Figure S6) , while the result of T-AOC was opposite to those mentioned above (Figure 7c ). To confirm that ROS had a key role in IgG enhanced tumor growth, we analyzed ROS level in human liver cancer tissues and normal liver tissues with DHE and DCFH-DA assays (Figure 8a, left panel) . The results showed that DHE or DCF mean density of liver cancer tissues was higher than that of normal liver tissues. The result of MDA content in liver cancer tissues was the same as one of DHE or DCF mean density, but different from that of T-AOC (Figure 8a, right panel) . The expressions of IgGg, PCNA, Ki67 and PRDX1 were also examined. Immunohistochemistry results indicated that the expressions of the first three proteins were upregulated in liver cancer tissues, but the expression of the last one was downregulated, compared with normal liver tissues (Figure 8a and Supplementary Figure S8a) . Similar results were obtained in lung cancer tissues and normal lung tissues (Figure 8b and Supplementary Figure S8b) or breast cancer tissues and normal breast tissues ( Supplementary  Figures S7 and 8c ).
Discussion
In this study, we first confirmed the expression of IgG in a number of cancer cell lines. We then explored the roles of cancer-derived IgG in cell growth and proliferation and established that downregulation of IgG suppressed the growth and proliferation of cancer cells and arrested cell cycle (S phase). In vivo, nude mouse tumorigenicity assay was carried out to confirm the above results. To elucidate its mechanism, we performed a co-immunoprecipitation assay and identified 27 cancer-derived IgG-associated proteins. Functional annotation identified RACK1, RAN and PRDX1 involved in cancer cell growth and oxidative stress, which prompted us to investigate the mechanism of action of cancerderived IgG in the above phenomena. Further experiments revealed that cancer-derived IgG enhanced cell growth and proliferation via inducing the production of ROS at low level in vitro and in vivo. These findings demonstrate that ROS have a pivotal role in IgG-induced growth and proliferation of cancer cells. The proposed mechanism is illustrated in Figure 9 .
Among the 27 candidate molecules, half of them are intimately correlated with cell growth or proliferation. For example, a ribosomal protein (RP) family, including RPL10L, RPL13, RPL13a, RPL15 and RPL18, has essential roles in protein synthesis and macromolecule metabolism. Interaction with these proteins suggests that cancer-derived IgG may promote cell growth and proliferation through regulating proteins related to metabolism or ribosomal protein family and activating the proliferative signaling pathway. In this study, IgG interacted with three proteins associated with cell growth, that is, RACK1, RAN and PRDX1, and these three proteins also interacted with each other. Therefore, the above four proteins are likely to form a macro-complex. It has been shown that nonenzymatic and enzymatic antioxidants, including ascorbic acid, vitamin E, GSH, SOD, CAT, GR and GPx, can efficiently safeguard against the accumulation of intercellular ROS such as O 2 À , H 2 O 2 and OH Á . [15] [16] [17] [18] [19] In our study, knockdown of IgG increased cellular total antioxidant capacity including activities of some antioxidant enzymes (total SOD, Mn-SOD, CuZn-SOD, CAT, GR, GPx), the expression level of PRDX1 and small molecular antioxidant (GSH) content. In contrast, the levels of corresponding target ROS molecules including O 2 À and H 2 O 2 decreased significantly, suggesting that cancer-derived IgG has a role in regulating cellular antioxidant response.
ROS is a double-edged sword. The harmful effects of ROS appear at a high level. Over production of ROS causes cellular damage, dysfunction, growth inhibition, and so on. [24] [25] [26] [27] However, the beneficial effects of ROS occur at low or moderate level and involve physiological roles in cellular responses, signaling and regulation. [28] [29] [30] It should be pointed out that the low or moderate level of ROS production is the level at which ROS participates in cellular normal physiological functions and provides essential protective mechanisms. The high level of ROS production is the level at which ROS will lead to deleterious effects such as membrane lipid peroxidation, protein oxidation, DNA damage and disturbance of cellular redox equivalents, which induce cell death, apoptosis and senescence. Therefore, the cutoff values to define Figure S7) low-moderate-high levels of ROS production is based on whether or not ROS does damage to normal physiological function of cells and the degree of free radical damage. In fact, there are different cutoff values to define low-moderate-high levels of ROS production in different cancer cells. In this study, according to the experimental results, the level or concentration of H 2 O 2 less than or equal to 2 mM is defined as low level, 2-1000 mM of H 2 O 2 is defined as moderate level and equal to or greater than 1000 mM is defined as high level. Studies have shown that cancer cells exhibiting an accelerated metabolism demand a relatively high ROS level to maintain their high proliferative rate. 31 ROS can promote many aspects of tumor development and progression that can be classified into the following four biological processes: (1) cellular proliferation, for example, ligand-independent receptor tyrosine kinase (RTK) activation and ERK1/2 activation; (2) evasion of apoptosis, for example, nuclear factor kappa B (NF-kB), Src and phosphatidylinositol-3 kinase (PI3K)/Akt activation; (3) angiogenesis, for example, the release of vascular endothelial growth factor (VEGF) and angiopoietin and (4) tissue metastasis and invasion, for example, metalloproteinase secretion into the extracellular matrix, and the interaction between Rho and Rac. 32, 33 Our results indicated that knockdown of cancer-derived IgG lowered cellular ROS levels via increasing the activities of antioxidant enzymes such as SOD, CAT, GR and GPx, the expression level of PRDX1 and GSH content. Therefore, under normal physiological conditions, IgG induces cancer cells to produce ROS at low level but not at moderate or high level through inhibiting the above antioxidant system, as the latter two are not beneficial to cancer cell growth. Previous studies have demonstrated that ROS at low level promoted cancer cells growth and proliferation. [34] [35] [36] In our study, ROS scavengers, including CAT, DMSO, NAC and SOD, further depressed the growth of IgG-deficient cells to different degrees by decreasing levels of intracellular ROS, whereas exogenous H 2 O 2 at low concentration reversed the depression of IgG-deficient cells by increasing the levels of intracellular ROS. Similar results were obtained in the ROS animal model and human tissues. The above findings establish that ROS acts as a key mediator in IgG-induced growth and proliferation of cancer cells. Figure 9 A schematic model of cancer-derived IgG to enhance cell growth and proliferation through inducing the production of a low level of ROS. Based on our findings, we propose the following mechanism. The interaction between IgG and RACK1, RAN and PRDX1 prompted us to explore the mechanism of action of cancer-derived IgG in cell growth and oxidative stress. Cancer-derived IgG decreased cellular total antioxidant capacity including activities of some antioxidant enzymes (SOD, CAT, GR and GPx), the expression level of PRDX1 and GSH content. The decreased total antioxidant capacity in turn induces production of a low level of intracellular ROS that activates MAPK/ ERK signaling pathway to enhance growth and proliferation of cancer cells
Signal transduction mechanism of cancer-derived IgG has not been reported previously. Our study found that downregulation of IgG decreased ERK phosphorylation. ROS scavengers further decreased ERK phosphorylation in IgG-deficient cells. In contrast, exogenous H 2 O 2 at low concentration recovered the reduction of ERK phosphorylation induced by knockdown of not only IgG but also IgG together with ROS scavengers. Similar results were obtained in the ROS animal model. MAPK/ERK pathway is an important signal transduction pathway and has a close relation with cell growth and differentiation. [37] [38] [39] Our findings strongly suggest that cancer-derived IgG activates MAPK/ ERK signaling pathway, leading to cell proliferation through inducing the production of intracellular ROS at low level.
In summary, cancer-derived IgG induced the production of intracellular ROS at low level via attenuating cellular total antioxidant capacity, which in turn promoted the growth and proliferation of cancer cell through activating MAPK/ERK signaling pathway. The proposed mechanism provides a new perspective to investigate functions of cancer-derived IgG and new clues for tumor biology. Further studies should be carried out to investigate details of this mechanism and their significance in cancer therapy. Immunoprecipitation and western blot analysis. Whole-cell lysates of HeLa cells were incubated with monoclonal mouse anti-human IgG antibody (g chain-specific) (Sigma, St. Louis, MO, USA) at 4 1C overnight, and then precipitated with 30 ul protein G agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h. Immunocomplexes were washed and boiled, separated by SDS-PAGE and then transferred to nitrocellulose membranes. Membranes were blocked with 5% bovine serum albumin in Tris-buffered saline containing 0.2-0.4% Tween-20 (TBST), and incubated with primary antibodies (Supplementary Table  S3 ) at 4 1C overnight. Western blotting was analyzed with Alex680-and IR700-conjugated secondary antibodies in a two-color LI-COR Odyssey Imaging System (LI-COR Biosciences, Lincoln, NE, USA).
Protein identification with mass spectrometry. Silver-stained SDS-PAGE gels were photographed, and the bands that differentiated between the experimental group with IgG antibodies and the control group with normal IgG were cut out. Protein samples were identified as previously described. 40 Immunohistochemistry and immunofluorescence. Immunohistochemistry was performed on paraformaldehyde-fixed samples as previously described. 7 Immunofluorescence was performed as previously described. 5 Confocal microscopic images were obtained with an Olympus confocal imaging system (Olympus, Tokyo, Japan).
RNA purification, RT-PCR and RT-qPCR. Total RNA was isolated from the cells using Trizol reagent (Invitrogen, Camarillo, CA, USA) and treated with RNase Free DNase (Invitrogen) to remove genomic DNA. Reverse transcription of total RNA was performed using PrimeScript RT reagent Kit Perfect Real Time (Invitrogen). Conventional, nested or semi-nested PCR was performed and the primers used in this study were listed in Supplementary Table S4 . RT-qPCR analysis was performed using the ABI7300 (Applied Biosystems, Foster City, CA, USA). The primers were shown in Supplementary Table S4 .
RNA interference. siRNAs were transfected into HeLa, PC3 and HEp-2 cells with X-tremeGENE siRNA Transfection Reagent (Roche Applied Science, Indianapolis, IN, USA). Cells were further analyzed 72 h after transfection. IGHG1 siRNA sequence was listed in Supplementary Table S5 .
Short tandem repeat analysis. Short tandem repeat analysis of the HeLa, HEp-2 and PC3 cell lines was performed by Beijing Microread Gene Technology Co., Ltd (Beijing, China) and Beijing JianLian Genes Technology Co., Ltd (Beijing, China). Analysis of tumor growth. Six female BALB/c nude mice were injected with control shRNA cells (group 1), IGHG1 shRNA cells (group 2) and IGHG1 shRNA cells (group 3). Cells (5 Â 10 7 in a volume of 200 ml normal saline) were injected subcutaneously into the bilateral groin. Tumor growth was monitored externally using vernier calipers for 8 weeks. When the diameters of tumor were 4.3 cm after injection, H 2 O 2 (2 mM) was directly injected into the tumor body of group 3 mice for 7 weeks. At 8 weeks after injection, all mice were killed after the photograph was taken. Their tumors were removed and partly fixed in 10% formalin, the other stored at À 70 1C.
Measurement of T-AOC, antioxidant enzyme activities, GSH content and H 2 O 2 level. The total antioxidant capacity was determined using a T-AOC Assay Kit with ferric reducing ability of plasma (FRAP) method (S0116, Beyotime, Shanghai, China) as previously described. 41 The activities of total SOD, CuZn/Mn-SOD, CAT, GR and GP X in the samples were determined using a Total SOD Assay Kit with WST (S0102, Beyotime), a CuZn/Mn-SOD Assay Kit with WST (S0105, Beyotime), a CAT Assay Kit (S0051, Beyotime), a GR Assay Kit (S0055, Beyotime) and a Total GP X Assay Kit (S0058, Beyotime) as previously described. [42] [43] [44] The GSH content was determined using GSH and GSSG Assay Kit (S0053, Beyotime) as previously described. 45 The H 2 O 2 content was determined using a H 2 O 2 Assay Kit (S0038, Beyotime) as previously described. 46 Statistical analysis. SPSS software (version 16.0; SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. All experiments were repeated at least three times. The data were expressed as the mean ± S.D. and compared with independent-samples t-test. The significant level was set at Po0.05.
